Author:
Skinner-Adams Tina S.,Peatey Christopher L.,Anderson Karen,Trenholme Katharine R.,Krige David,Brown Christopher L.,Stack Colin,Nsangou Desire M. M.,Mathews Rency T.,Thivierge Karine,Dalton John P.,Gardiner Donald L.
Abstract
ABSTRACTMalaria remains a significant risk in many areas of the world, with resistance to the current antimalarial pharmacopeia an ever-increasing problem. The M1 alanine aminopeptidase (PfM1AAP) and M17 leucine aminopeptidase (PfM17LAP) are believed to play a role in the terminal stages of digestion of host hemoglobin and thereby generate a pool of free amino acids that are essential for parasite growth and development. Here, we show that an orally bioavailable aminopeptidase inhibitor, CHR-2863, is efficacious against murine malaria.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Cited by
36 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献